Benefit-Risk Assessment of Telithromycin in the Treatment of Community-Acquired Pneumonia

ISSN： 0114-5916

Source： Drug Safety, Vol.31, Iss.7, 2008-01, pp. : 561-575

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current treatment of community-acquired pneumonia

By Liapikou Adamantia

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1319-1332

Informa Healthcare

Access to resources Recommend Favorite

Community acquired pneumonia: assessment and treatment

By Patterson Caroline M Loebinger Michael R

Clinical Medicine, Vol. 12, Iss. 3, 2012-06 ,pp. : 283-286

Royal College Of Physicians

Access to resources Recommend Favorite

Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia

By Shi Jun

Clinical Pharmacokinetics, Vol. 44, Iss. 3, 2005-01 ,pp. : 317-329

Adis International

Access to resources Recommend Favorite

Community-Acquired Pneumonia in the Elderly: A Practical Guide to Treatment

By Lieberman D.

Drugs & Aging, Vol. 17, Iss. 2, 2000-08 ,pp. : 93-105

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

By Dienstmann Rodrigo

Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. : 15-25

Adis International

Access to resources Recommend Favorite